Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Histologically confirmed unresectable Stage III or IV melanoma~* Treatment-naive or experienced disease recurrence or progression during or after one prior systemic regimen for advanced disease~* Measurable disease by Computed Tomography/Magnetic resonance imaging (CT/MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Known BRAF V600 mutation status or consent to BRAF V600 mutation testing~* Sufficient tumor tissue accessible for baseline and post-treatment biopsies.~Exclusion Criteria:~* Active central nervous system (CNS) metastases~* Carcinomatous meningitis~* Active, known or suspected autoimmune disease~* Condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization~* Prior therapy with anti-Programmed Death-1 (PD1), anti-Programmed Death-Ligand 1 (PD-L1), anti-PD-L2, anti-CD137, or anti-CTLA-4 (cytotoxic T lymphocyte antigen 4) antibody~* Prior treatment with other immunotherapies~* Prior therapy with BRAF inhibitor within 6 weeks of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: Nivolumab followed by Ipilimumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.
- Cohort B: Ipilimumab followed by Nivolumab (Type: EXPERIMENTAL): Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).